The conference agenda has been curated to provide exclusive insights on emerging trends to position yourself at the forefront of the pharmaceutical landscape, while creating the space to forge invaluable partnerships.

NORTH BETHESDA, Md. (PRWEB)
June 22, 2023

The International Society for Pharmaceutical Engineering (ISPE) is thrilled to announce Joydeep Ganguly, Senior Vice President of Corporate Operations at Gilead Sciences Inc, as the Executive Chair of the 2023 ISPE Annual Meeting & Expo. The event will take place from 15-18 October at the Mandalay Bay Resort in Las Vegas, Nevada, USA.

The 2023 ISPE Annual Meeting & Expo will offer a diverse range of content areas that delve into critical issues shaping the pharmaceutical industry. The robust program will offer more than 53 hours of educational content covering fundamental topics such as digital transformation, manufacturing excellence, regulatory compliance, supply chain resiliency, advanced therapy and manufacturing, and sustainability. It will also feature a Global Regulatory Town Hall and six interactive workshops on operational excellence, regulatory issues, digitalization, and more. The prestigious Facility of the Year Awards banquet, which recognizes outstanding achievements in pharmaceutical manufacturing facility design and operation, will take place during the conference.

“I am honored and privileged to serve as the Executive Chair for the 2023 ISPE Annual Meeting & Expo,” said Ganguly. “This remarkable event is a pivotal gathering that brings together innovators within the industry to ignite the pharmaceutical industry. Please join me and other thought leaders as we look to share how latest advancements in our sector are shaping the future of our industry. The conference agenda has been curated to provide exclusive insights on emerging trends to position yourself at the forefront of the pharmaceutical landscape, while creating the space to forge invaluable partnerships.”

In addition to collaborating, exchanging ideas, and learning with thousands of industry colleagues and leaders from around the world, conference attendees will also be able to participate in an array of networking and social activities including a hackathon and a golf tournament hosted by the ISPE Foundation.

In his current role as Senior Vice President of Corporate Operations at Gilead Sciences, Ganguly oversees Gilead’s global operations across its network. Before Gilead, Joydeep spent 10 years at Biogen in roles of increasing responsibility in technical operations, manufacturing and supply chain. A transformational thought leader in the operations space, he has published extensively about operations transformation, engineering innovation and supply chain evolution. Joydeep earned a Master of Science in Electrical Engineering from the University of Notre Dame, a Master of Business Administration from North Carolina State University, and a master’s degree in healthcare administration from Cornell University. Recently recognized as a Top 50 Diverse Leader in California, Joydeep sits on the Boards of the Bay Area Council, Biocom, the Gilead Foundation, and was recently appointed to the Board of Advisors at Culture Biosciences.

Registration for the 2023 ISPE Annual Meeting & Expo is now open: https://ispe.org/AM23

About ISPE

“The International Society for Pharmaceutical Engineering (ISPE) is a global nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 20,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, and technical, regulatory, and compliance collaborations in more than 120 countries worldwide. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. For more information, visit ISPE.org.

Share article on social media or email:

The 2023 American Academy of Facial Plastic and Reconstructive Surgery conference features Advances in Rhinoplasty & Facial Rejuvenation

SAN DIEGO (PRWEB)
June 22, 2023

Board-certified facial plastic surgeon Dr. Neil A. Gordon is honored to be invited to present multiple lectures, including advanced deep plane face lifting techniques, at the American Academy of Facial Plastic Reconstructive Surgery (AAFPRS) annual meeting on April 27-30th at the Manchester Grand Hyatt Hotel in San Diego, California.

The 2023 American Academy of Facial Plastic and Reconstructive Surgery conference features Advances in Rhinoplasty & Facial Rejuvenation. The meeting provides clinical and professional education for advanced care providers, fellows in training, residents, and surgeons in the field of Facial plastic and reconstructive surgery, oculoplastic surgery, aesthetic medicine, Dermatology, maxillofacial surgery, otolaryngology head and neck surgery, and professionals providing surgical and nonsurgical treatments to enhance, restore and rejuvenate the face.

The AAFPRS creates this annual event to provide the best education, featuring elite medical professionals specializing in rhinoplasty and facial rejuvenation. The 2023 event features top surgical specialists, including Dr. Neil Gordon, and the best minds in facial plastic and reconstructive surgery.

Dr. Gordon will give multiple presentations at the annual event, including Deep-Plane Facelift Techniques, Advanced Deep-Plane Facelifting Techniques at the Seaport A Breakout, a Panel discussion on Advanced Deep-Plane Facelifting Techniques, Pearls from 27 Years of Deep-Plane Facelifting, and more.

Dr. Gordon’s Advancements in Facelift and Facial Rejuvenation

Dr. Gordon’s facelift and facial rejuvenation research, development, and techniques are recognized internationally. His significant advancements in facial rejuvenation, including the Vertical Galae Advancement and the Vertical Platysma Advancement, are studied worldwide.

Dr. Gordon is a recognized facial rejuvenation expert and has taught on numerous panels, including seminars and master classes on:

• 
  Controversies in Facelifting with the Experts
• Revision Rhytidectomy
• Deep Plane Rhytidectomy: Modifications, Nuances, and Observations- a 25-Year Experience
• The Forehead Lift, It’s Not About Lifting the Eyebrows

Dr. Neil Gordon is recognized worldwide by plastic surgeons as a facial rejuvenation expert and master in Italy, Australia, Brazil, Germany, India, Mexico, Columbia, and more. For over a decade, he has presented his specialized techniques, research, and outcomes.

Dr. Gordon has written his advancements and expertise in multiple academic textbooks and scientific journals in the US and abroad. The reality TV show “Botched” was based on Dr. Neil Gordon’s work as a revision plastic surgeon fixing bad results.

Dr. Gordon’s Retreat at Split Rock in Wilton, CT

Dr. Neil A. Gordon founded The New England Surgical Center, LLC, a state-licensed, fully-accredited outpatient surgical center located at the gorgeous getaway The Retreat at Split Rock in Wilton, CT. The surgical facility complies with the same regulations and inspections as hospitals. It is recognized for its gold-standard safety, comfort, and privacy and is fully accredited by the AAAASF.

The state-of-the-art facility sits on a tranquil and elegant private country estate. It is the perfect place to experience facial rejuvenation in luxury and comfort while in the trusted care of leading, internationally-respected facial plastic surgeon Dr. Neil Gordon. Patients travel internationally to experience the exquisite results made possible by Dr. Gordon’s extensive research, years of study, and decades of experience performing primary, revision, and secondary procedures.

Dr. Gordon and his talented staff prioritize rapid recovery, as most patients must return to their professional and social life within 9 to 14 days. Dr. Gordon focuses on individualized care to ensure predictability and outcomes, minimize swelling and bruising, and optimize recovery. By limiting his schedule to one facial rejuvenation procedure a day and performing every aspect of the surgery himself, Dr. Gordon is uniquely able to produce consistently superior results with meticulous attention to every detail.

The adjacent R & R Retreat at Split Rock eliminates travel stress and allows patients to enjoy an anxiety-free, rapid recovery. The Inn is not a medical recovery facility. It provides unique recovery treatments, including oxygen therapy, lymphatic massage, and nutritional support, to ensure that each patient experiences unparalleled advantages for a smooth, uncomplicated recovery.

Dr. Gordon Awards and Recognition

Dr. Gordon is a multi-board certified doctor and the recipient of multiple awards, including New York Magazine’s Best Doctor, America’s Best Doctors by US News and World, and one of the Top Doctors in the New York Metro area by Castle Connolly, LTD. Dr. Gordon is also listed in the Top 101 Doctors and recognized by the Best Doctors Inc. and Best Doctors in America: The Guide to America’s Top Physicians: Consumer Research Council of America.

Dr. Gordon is a down-to-earth, compassionate, caring doctor who feels honored to present his advances in facial rejuvenation and deep-plane facelift at the American Academy of Facial Plastic Reconstructive Surgery 2023 Conference in San Diego, CA.

###

Visit The Retreat at Split Rock located in Wilton, CT, Greenwich, CT, or New York, NY, or call (203) 834-7700 to schedule a consultation with board-certified facial plastic surgeon Dr. Neil Gordon, M.D.

NEW YORK (PRWEB)
June 22, 2023

NFP, a leading property and casualty broker, benefits consultant, wealth manager, and retirement plan advisor, has released TPCompare, a pricing and comparative analysis tool for healthcare delivery systems. TPCompare benchmarks data from providers, facilities and payers and then compares the cost and quality scoring of medical procedures and services against other healthcare delivery systems.

“Recently enacted legislation requires hospitals and payers to establish, update and make public their healthcare procedural charges for in-network services,” said Kim Bell, head of Health & Benefits, NFP. “While very few market players have built a solution suitable for healthcare delivery systems in today’s price transparency environment, TPCompare provides visibility into formerly trade secret commercial pricing that can create a competitive advantage opportunity aimed at hospitals and health systems.”

E. Heidi Cottle, national practice leader, SVP, Cost Containment Strategies, NFP, led the development of TPCompare. Cottle, who has been helping NFP clients manage healthcare costs since 2013, is a healthcare cost containment specialist with more than 30 years of leadership experience across employee benefits. In this role, Cottle is elevating efforts to usher in the next generation of healthcare pricing and delivery structures.

“TPCompare brings cost transparency data to another level, supported by enhanced data sets that produce a detailed view and accuracy to the analytics,” said Cottle. “The tool empowers healthcare providers to negotiate competitive pricing from a position of strength by independently validating quantitative and qualitative data for medical procedures and services against a comprehensive competitor database. This creates a higher level of cost accountability, focused on quality metrics, to measure overall outcome improvement for stakeholders.”

About NFP

NFP is a leading property and casualty broker, benefits consultant, wealth manager, and retirement plan advisor that provides solutions enabling client success through the expertise of over 7,400 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors and financial institutions. NFP is the 9th best place to work for large employers in insurance, 7th largest privately-owned broker, 5th largest benefits broker by global revenue and 13th largest broker of US business (all rankings according to Business Insurance).

Visit NFP.com to discover how NFP empowers clients to meet their goals.

Share article on social media or email:

GRI is an exciting new tool in the toolkit for clinicians and Rimidi is committed to bringing this innovation into the clinical workflow.

ATLANTA (PRWEB)
June 22, 2023

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management.

“As continuous glucose monitoring (CGM) gains broader adoption and becomes standard of care in patients with Type 2 Diabetes and primary care, clinicians need strategies for effectively triaging their growing population of patients using CGM and identifying appropriate steps to improve glycemic control,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “GRI is an exciting new tool in the toolkit for clinicians and Rimidi is committed to bringing this innovation into the clinical workflow.”

The inclusion of CGM data and GRI into Rimidi’s platform and clinical workflows is made possible via an enhanced integration with Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions.

Today, more than 37 million people in the US, or about 11% of the population, live with diabetes. If not properly controlled, the disease can lead to other comorbidities, such as heart disease, obesity and kidney failure, further contributing to worse health outcomes and additional healthcare costs. For these patients, taking frequent glucose level checks is critical.

Specifically, the Rimidi diabetes management platform will now include metrics for:

• 
  Time in Range (TIR): The amount of time a patient spends in the target blood glucose range during a specified time period, often two weeks. For most patients, this is between 70 and 180 mg/dL, and is a measurement that leverages CGM data to see the number of times a patient’s blood glucose level has stayed in the target range vs. been high (hyperglycemia) or low (hypoglycemia). TIR is considered the gold standard of CGM data management and interpretation today. Rimidi presents the TIR for target glucose as well as additional categories of low, very low, high and very high glucose.
• Glycemic Risk Index: A new actionable metric for describing the quality of glycemia in CGM tracking, developed by the Diabetes Technology Society. This metric can be used to assess how well a patient is doing over time, manage a population and predict outcomes in intervention studies. The composite score is also thought to better correlate with the risk of complications and help identify areas for therapy adjustment. The use of GRI in clinical practice is just beginning to gain adoption.

Rimidi’s diabetes management platform combines patient-generated data from CGMs and other connected devices, with relevant clinical data in EHR systems, allowing clinicians to see all of the important data for diabetes care, including medications, latest laboratory results, and diagnoses, within their EHR, to drive patient-specific clinical actions through embedded Clinical Decision Support cards. These new enhancements will further enable clinicians to manage their diabetes patients and empower patients to make lifestyle changes.

“Adoption and application of CGM technology continues to evolve and expand. Dexcom is at the forefront of this innovation to help simplify and improve diabetes management for patients and clinicians,” said Scott Odgers, Senior Director Strategic Accounts, Dexcom. “We’re proud to integrate with Rimidi and leverage our innovative CGM technologies to further empower patients to take control of health.”

For more information on Rimidi and its newly enhanced diabetes management platform, visit rimidi.com/solutions/diabetes.

Members of the Rimidi and Dexcom teams will also be at the American Diabetes Association’s 83rd Scientific Sessions 2023 in San Diego, CA from June 23-26. To book a meeting with Dr. Ide at the conference, please reach out to rimidi@alloycrew.com.

About Rimidi

Created by doctors, Rimidi’s leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and achieve quality objectives. By bringing together clinical decision support, remote patient monitoring and patient reported outcomes in a unified, composable, FHIR-based platform, Rimidi supports a broad range of clinical use cases and institutional priorities across large and small healthcare organizations. For more information, visit rimidi.com and follow us on Twitter and LinkedIn.

Share article on social media or email:

A thought leader in the fields of quality systems, regulatory compliance and the implementation of enterprise software across manufacturing, Goodman is well-equipped to guide the conversation on enhancing infrastructure and improving technology in life sciences companies.

TORONTO (PRWEB)
June 22, 2023

In an era where digital transformation is disrupting traditional systems and paving the way for innovative solutions, it becomes crucial to address the challenges faced in quality management. In this light, a highly informative, free webinar is set to discuss how to modernize Quality Management Systems (QMS) and look towards a future with connected life sciences.

The webinar aims to shed light on the fact that there is no “one-size-fits-all” solution for every organization. It will address the issues caused by this approach, including business disruptions, upheaval of existing systems, gaps in critical applications and limitations on data-driven decisions.

The featured speaker for the event is Joe Goodman, the Global Vice President of Solutions Engineering and Customer Engagement at Sparta Systems, a Honeywell Company. A thought leader in the fields of quality systems, regulatory compliance and the implementation of enterprise software across manufacturing, Goodman is well-equipped to guide the conversation on enhancing infrastructure and improving technology in life sciences companies.

The webinar will provide insights on modernizing legacy platforms, creating IT-friendly data structures, bringing quality systems up to par with other pillar systems and how digital platforms can satisfy both IT’s need for standardization and business needs for best-in-class solutions.

Sparta Systems, a Honeywell Company, is a leader in its field, driving smart quality with AI-enabled quality solutions. For nearly three decades, the company has been providing enterprise and cloud-based QMS software solutions. Sparta Systems simplifies the process of quality management and guides customers towards proactive quality.

Sparta Systems has partnered with Xtalks for this webinar. Don’t miss this opportunity to learn about the future of quality management in life sciences. The free webinar is scheduled for Tuesday, July 11, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Modernizing Quality Management Systems: Look to the Future with Connected Life Sciences.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

ARLINGTON, Va. (PRWEB)
June 22, 2023

Radiation therapy’s growth was mixed in 2022, with treatment visits declining 2.8% year-over-year but the number of treatment courses increasing by 2.9%, according to a new report published by IMV Medical Information Division.

But these particular data points in the report — called the IMV 2022-2023 Radiation Therapy Market Summary – reflect a gain in the efficiency of treating patients with radiation therapy, in part due as well to a 5.4% decrease in the average number of visits per course of treatment, report lead and IMV senior market research program manager Davin Korstjens said.

“The reduction in the number of radiation therapy treatment visits needed per course of treatment is a trend that we have seen continue over the past several years and shows meaningful progress toward improving the experience for patients undergoing treatments,” he told AuntMinnie.com.

The report also found that, although the external beam radiation therapy installed base in the U.S. decreased by 3.3% in 2022, 50% of radiation therapy sites are considering the purchase of an EBRT system in the next three years, Korstjens said. In 2022, 40% of radiation therapy sites reported having brachytherapy units, and 15% of survey participants stated they are considering the purchase of a brachytherapy unit over the next three years.

Finally, in regards to image-guided radiation therapy equipment, 97% of sites that participated in the survey have this equipment installed, with the top three modalities being CT or cone beam CT, x-ray, and surface guidance radiation therapy.

“The gains in radiation therapy treatment efficiency seen so far are impressive and it will be interesting to continue to watch this metric to see where the trend will ultimately land,” Korstjens said.

Want to share your knowledge of medical imaging? Click here to sign up for the IMV Survey panel today.

Davin Korstjens is a Senior Market Research Program Manager at IMV Medical Information Division, part of Science and Medicine Group.

IMV’s 2022-2023 Radiation Therapy Market Summary Report explores market trends in U.S. hospitals and imaging centers, including procedure volume, manufacture-installed base features and share, the use of OEM vs. third-party service providers, purchase plans, brand loyalty, and site operations characteristics. The report was published in June 2023 and is based on responses from 312 radiology/departmental administrators and clinicians who participated in IMV’s nationwide survey from August 2021-April 2023. Vendors covered in this report include Accuray, Brainlab, Cerner, Elekta, Epic Varian, Elekta, Gammamed, GEHC, IBA, Nucletron, RaySearch, Siemens, Varian, View Ray, Vision RT and Xoft.

For information about purchasing IMV Market Outlook Reports, visit the corporate website at https://imvinfo.com/ or call 703-778-3080 ext. 1033 to speak with a representative. In addition to the report, all purchases will include a complimentary recording of an executive summary presentation of findings conducted by IMV’s Senior Program Manager.

Disclosure: IMV Medical Information Division is a sister company of AuntMinnie.com.

Share article on social media or email:

Dallas Rhinoplasty Surgeon, Dr. Rod J. Rohrich

“In rhinoplasty it’s not enough to be consistent, you must be consistently exceptional.” -Dr. Rod J. Rohrich

DALLAS (PRWEB)
June 22, 2023

The Journal of Plastic and Reconstructive Surgery, the official peer review journal of the American Society of Plastic Surgeons and the leading plastic surgery journal globally, has selected Dr. Rohrich’s article, “Personal Evolution in Rhinoplasty Tip Shaping: Beyond the Tripod Concept,” to be included in the Journal’s “Best of PRS” collection of outstanding contributions to cosmetic surgery.

The article challenges the principles of rhinoplasty tip surgery and details an algorithmic approach to obtain consistent nasal tip shaping. The modernized techniques described in the paper have modified the “tripod concept” which has been used for over 50 years, and involves selective lower lateral cartilage reshaping, maximum tensioning, and managing the soft-tissue envelope. The article also discusses the intraoperative sequencing and key technical considerations related to this approach.

Dr. Rohrich describes rhinoplasty as, “a surgery of millimeters” that epitomizes plastic surgery by its extremely narrow range of contrast between what would be considered a good outcome and a poor one. He strongly advocates for the open approach to rhinoplasty which gives surgeons direct access to the delicate underlying nasal anatomy and allows for an individualized approach to rhinoplasty.

“It remains one of the most challenging surgical procedures in all of plastic surgery,” he says.

Dr. Rohrich, a global rhinoplasty expert, writes and lectures extensively on both rhinoplasty and revision rhinoplasty and states that this new tip shaping refinement is significant by adding much more clarity on having better and more consistent rhinoplasty outcomes.

“The modernized techniques outlined in this paper allow for improved and more uniform tip rotation and change in tip projection,” explains Dr. Rohrich. “In rhinoplasty it’s not enough to be consistent, you must be consistently exceptional.”

About Rod J. Rohrich, M.D., F.A.C.S.

Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He is considered one of the most influential surgeons in this century. He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021, 2022 and 2023. Dr. Rohrich is a Clinical Professor of Plastic Surgery at Baylor College of Medicine. He was the first Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors, and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.

He is the immediate past (after serving for 18 years) Editor-in-Chief of the most respected global peer reviewed plastic surgery journal – the Plastic and Reconstructive Surgery Journal. He is Founding Editor-in-Chief/Editor Emeritus of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 1000 peer reviewed articles and seven textbooks in plastic surgery including a best-selling medical book entitled The Facial Danger Zones. Dr. Rohrich recently published an innovative cosmetic surgery video atlas, Cosmetic Surgery by the Masters.

Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America’s best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession’s highest honors, the Plastic Surgery Foundation (PSF) Distinguished Service Award, which recognizes his contributions to education in plastic surgery. In addition, he has also been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations. He is also the recipient of the ASPS 2022 Honorary Citation.

Share article on social media or email: